Blotta et al. suggested that the simultaneous use of GLI- and SMO-inhibitors serve as a more potent combination therapy in multiple myeloma for inhibiting the HH signaling cascade at multiple interfaces [43]. This evidence concerns the gene GLI1 and AL amyloidosis.